Difference between revisions of "Ondansetron (Zofran)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "[http://online.lexi.com/ Lexicomp]" to "Lexicomp")
 
(17 intermediate revisions by 4 users not shown)
Line 1: Line 1:
 
==General information==
 
==General information==
−
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist.  Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.<ref name=insert>[https://www.gsksource.com/gskprm/htdocs/documents/ZOFRAN-ORAL.PDF Ondansetron (Zofran) package insert]</ref><ref>[[Media:Ondansetron.pdf | Ondansetron (Zofran) package insert (locally hosted backup)]]</ref>
+
Class/mechanism: Selective serotonin 5-HT3 receptor antagonist.  Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.<ref name=insert>[http://www.pharma.us.novartis.com/product/pi/pdf/zofran.pdf Ondansetron (Zofran) package insert]</ref><ref>[[:File:Ondansetron.pdf | Ondansetron (Zofran) package insert (locally hosted backup)]]</ref>
 
<br>Route: PO, IV
 
<br>Route: PO, IV
 
<br>Extravasation: no information available
 
<br>Extravasation: no information available
  
−
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
  
 
==Patient drug information==
 
==Patient drug information==
 +
*Patient counseling information can be found in the [http://www.pharma.us.novartis.com/product/pi/pdf/zofran.pdf Ondansetron (Zofran) package insert]<ref name="insert"></ref>
 
*[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]</ref>
 
*[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/ondansetron-patient-drug-information Ondansetron (Zofran) patient drug information (UpToDate)]</ref>
 +
 +
==History of changes in FDA indication==
 +
* 1991-01-04: Initial FDA approval
  
 
==Also known as==
 
==Also known as==
−
Ondansetron HCL, ondansetron ODT, ondansetron oral solution, ondansetron orally disintegrating tablets, zofran HCL, zofran ODT, zofran oral solution, zofran orally disintegrating tablets.
+
*'''Code name:''' SN-307
 +
*'''Brand names:'''
 +
{| class="wikitable" style="text-align:center;"
 +
!colspan="8" align="center" style="background-color:#0066FF"| '''Synonyms'''
 +
|-
 +
|Alencar
 +
|Amilene
 +
|Ansentron
 +
|Anset
 +
|Atossa
 +
|Bryterol
 +
|Cedantron
 +
|Ceramos
 +
|-
 +
|Danofran
 +
|Dantenk
 +
|Emeran
 +
|Emeset
 +
|Emetra
 +
|Emetron
 +
|Emigo
 +
|Emistat
 +
|-
 +
|Emivox
 +
|Espasevit
 +
|Finaber
 +
|Finoxi
 +
|Frazon
 +
|Glendan
 +
|Helmine
 +
|Injectrax
 +
|-
 +
|Insetron
 +
|Invomit
 +
|Izofran
 +
|Latran
 +
|Modifical
 +
|Narfoz
 +
|Nausedron
 +
|Nautah
 +
|-
 +
|Neomit
 +
|Nuset
 +
|O.N.D.
 +
|Odanex
 +
|Odanse
 +
|Ometic
 +
|Omstron
 +
|Onaset
 +
|-
 +
|Oncotor
 +
|Onda
 +
|Ondace
 +
|Ondan
 +
|Ondanles
 +
|Ondansetron-Z
 +
|Ondant
 +
|Ondaren
 +
|-
 +
|Ondasetron
 +
|Ondatie
 +
|Ondavell
 +
|Ondem
 +
|Ondemet
 +
|Onfran
 +
|Onilat
 +
|Onsat
 +
|-
 +
|Onseran
 +
|Onset
 +
|Onsetron
 +
|Onsett
 +
|Onsia
 +
|Ontrax
 +
|Onzod
 +
|Osetron
 +
|-
 +
|Ostasyn
 +
|Otobrol
 +
|Periset
 +
|Quimiofran
 +
|Seton
 +
|Setronax
 +
|Setronon
 +
|Sopran
 +
|-
 +
|Trorix
 +
|Vomceran
 +
|Vomiban
 +
|Vomigo
 +
|Vomikind
 +
|Vomiset
 +
|Vomitron
 +
|Vomiz
 +
|-
 +
|Vonau
 +
|Yatrox
 +
|Zantron
 +
|Zapron
 +
|Zemitron
 +
|Zofer
 +
|Zofran
 +
|Zofran ODT
 +
|-
 +
|Zofron
 +
|Zoltem
 +
|Zonax
 +
|Zondan
 +
|Zophren
 +
|Zudan
 +
|Zuplenz
 +
|}
  
 
==References==
 
==References==
 +
* Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000 May 25;342(21):1554-9. [https://doi.org/10.1056/NEJM200005253422102 link to original article] [https://pubmed.ncbi.nlm.nih.gov/10824073/ PubMed]
 
<references/>
 
<references/>
  
−
[[Category:Drug index]]
+
[[Category:Drugs]]
 +
[[Category:Oral medications]]
 +
[[Category:Intravenous medications]]
 
[[Category:Emesis prevention]]
 
[[Category:Emesis prevention]]
 
[[Category:Serotonin 5-HT3 antagonists]]
 
[[Category:Serotonin 5-HT3 antagonists]]
 +
 +
[[Category:FDA approved in 1991]]
 +
[[Category:WHO Essential Pain and Palliative Care Medicine]]

Latest revision as of 12:13, 29 June 2024

General information

Class/mechanism: Selective serotonin 5-HT3 receptor antagonist. Chemotherapy medications can cause nausea and vomiting by stimulating release of serotonin from the enterochromaffin cells of the small intestine, and serotonin triggers the vomiting reflex by binding to and activating 5-HT3 receptors. Ondansetron prevents nausea and vomiting by binding with high affinity to 5-HT3 receptors and blocking their activation by serotonin.[1][2]
Route: PO, IV
Extravasation: no information available

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

History of changes in FDA indication

  • 1991-01-04: Initial FDA approval

Also known as

  • Code name: SN-307
  • Brand names:
Synonyms
Alencar Amilene Ansentron Anset Atossa Bryterol Cedantron Ceramos
Danofran Dantenk Emeran Emeset Emetra Emetron Emigo Emistat
Emivox Espasevit Finaber Finoxi Frazon Glendan Helmine Injectrax
Insetron Invomit Izofran Latran Modifical Narfoz Nausedron Nautah
Neomit Nuset O.N.D. Odanex Odanse Ometic Omstron Onaset
Oncotor Onda Ondace Ondan Ondanles Ondansetron-Z Ondant Ondaren
Ondasetron Ondatie Ondavell Ondem Ondemet Onfran Onilat Onsat
Onseran Onset Onsetron Onsett Onsia Ontrax Onzod Osetron
Ostasyn Otobrol Periset Quimiofran Seton Setronax Setronon Sopran
Trorix Vomceran Vomiban Vomigo Vomikind Vomiset Vomitron Vomiz
Vonau Yatrox Zantron Zapron Zemitron Zofer Zofran Zofran ODT
Zofron Zoltem Zonax Zondan Zophren Zudan Zuplenz

References

  • Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000 May 25;342(21):1554-9. link to original article PubMed
  1. ↑ 1.0 1.1 1.2 Ondansetron (Zofran) package insert
  2. ↑ Ondansetron (Zofran) package insert (locally hosted backup)
  3. ↑ Ondansetron (Zofran) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Ondansetron_(Zofran)&oldid=87790"